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Provider-initiated symptom screening for tuberculosis in 
Zimbabwe: diagnostic value and the effect of HIV status
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Objective To assess the diagnostic value of provider-initiated symptom screening for tuberculosis (TB) and how HIV status affects it.
Methods We performed a secondary analysis of randomly selected participants in a community-based TB–HIV prevalence survey in 
Harare, Zimbabwe. All completed a five-symptom questionnaire and underwent sputum TB culture and HIV testing. We calculated the 
sensitivity, specificity, and positive and negative predictive values of various symptoms and used regression analysis to investigate 
the relationship between symptoms and TB disease.
Findings We found one or more symptoms of TB in 21.2% of 1858 HIV-positive (HIV+) and 9.9% of 7121 HIV-negative (HIV−) participants 
(P < 0.001). TB was subsequently diagnosed in 48 HIV+ and 31 HIV− participants. TB was asymptomatic in 18 culture-positive individuals, 
8 of whom (4 in each HIV status group) had positive sputum smears. Cough of any duration, weight loss and, for HIV+ participants 
only, drenching night sweats were independent predictors of TB. In HIV+ participants, cough of ³ 2 weeks’ duration, any symptom 
and a positive sputum culture had sensitivities of 48%, 81% and 65%, respectively; in HIV− participants, the sensitivities were 45%, 
71% and 74%, respectively. Symptoms had a similar sensitivity and specificity in HIV+ and HIV− participants, but in HIV+ participants 
they had a higher positive and a lower negative predictive value.
Conclusion Even smear-positive TB may be missed by provider-initiated symptom screening, especially in HIV+ individuals. Symptom 
screening is useful for ruling out TB, but better TB diagnostics are urgently needed for resource-poor settings.
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Introduction
Symptom questionnaires provide a quick, cheap and convenient 
way to identify individuals at a high risk of tuberculosis (TB) 
disease, termed TB suspects, who then need investigation with 
more definitive tests such as sputum microscopy, chest radi-
ography and, when available, TB culture. Symptom screening 
for TB has high sensitivity when used to define TB suspects 
among patients who present themselves to health-care facilities 
for investigation of ill-health (i.e. passive case-finding) and is a 
key component of the the World Health Organization’s DOTS 
strategy for combating TB. In particular, chronic cough was 
found to be both highly sensitive and to have a reasonably high 
positive predictive value for smear-positive TB at the primary 
health-care level in studies in the pre-HIV era leading up to the 
development of the DOTS strategy.1–3
More recently, provider-initiated TB screening (i.e. ac-
tive case-finding) has become an important part of HIV care 
in resource-poor settings.4–8 Ruling out active TB is necessary 
both for individual patient management and for TB infec-
tion control. Symptom screening is often the only practical 
approach but, at least in HIV-negative (HIV−) individuals, 
TB symptom screening is considerably less sensitive when 
used for provider-initiated TB screening than when applied 
to patients who have self-presented for the investigation of 
ill health.9–15 Evidence is mounting that this may also be 
true for HIV-positive (HIV+) individuals.5–8,12–16 Screening 
failure can have major adverse consequences. In patients 
starting antiretroviral therapy, undiagnosed TB is common 
and carries a substantially increased risk of death or hospital-
ization in the first few months of treatment.8,17 Institutional 
outbreaks of TB have caused high morbidity and mortality 
among HIV-infected outpatients, especially in South Africa.18 
Perhaps most seriously, isoniazid preventive therapy is rarely 
used in Africa, despite its proven effectiveness for prevent-
ing HIV-related TB: fear of the consequences of screening 
failure and the subsequent risk of generating drug resistance 
is one of the major reasons for this implementation failure.19
In this study, we evaluated different approaches to TB 
screening in participants of a population-based HIV and TB 
prevalence survey in Harare, Zimbabwe. A TB symptom ques-
tionnaire was administered, and all participants were screened 
by sputum culture (even if asymptomatic) and followed-up 
to confirm or exclude TB. The main aim of this study was 
to investigate the effect of HIV on the prevalence of TB 
symptoms and on the diagnostic utility of different screening 
strategies among survey participants not being treated for TB.
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Methods
Participants and setting
Details of recruitment into the preva-
lence survey have been described more 
fully elsewhere.20 Briefly, a population-
based survey was carried out in 2005–
2006 among a random sample of adults 
in 46 previously enumerated neigh-
bourhoods in the high-density suburbs 
of Harare. Participants were asked to 
answer a questionnaire, provide blood 
for anonymized HIV serum testing and 
provide two sputum specimens (one 
“spot” specimen and one early morn-
ing specimen) for TB culture. Volun-
tary HIV counselling and testing was 
provided separately through outreach 
clinics by the New Start Centre, Harare, 
Zimbabwe.
Definition and follow-up of TB 
suspects
A TB suspect was defined as an in-
dividual with any TB symptom (de-
fined below) or who tested positive 
on sputum culture during screening 
(i.e. culture-positive). Consequently, 
asymptomatic culture-negative TB 
would not have been detected. The 
TB symptoms considered were: cur-
rent cough of any duration or severity, 
haemoptysis during the previous year, 
self-reported fever or “hot body”, night 
sweats and a subjective report of weight 
loss. Individuals who reported night 
sweats were asked whether they had to 
change their bed clothes or sheets (i.e. 
drenching night sweats) or not (i.e. 
mild night sweats). An enquiry was 
made about the duration (in weeks) 
of any reported symptoms. Cough was 
defined as acute if less than 2 weeks’ 
duration and as chronic otherwise. 
Smoking history and alcohol intake, as-
sessed using the Alcohol Use Disorders 
Identification Test questionnaire,21 were 
also recorded.
In addition, TB suspects under-
went follow-up testing, which included 
repeat sputum microscopy and culture 
and chest radiography, until TB was 
confirmed or excluded. A standard al-
gorithm was used to investigate possible 
cases of culture-negative TB: it included 
analysing clinical and radiological re-
sponses to broad-spectrum antibiotics 
and the response to TB treatment at 
1 month, where applicable.
Case definitions for TB disease
A case of TB disease was not diagnosed 
on the basis of screening results alone 
and subsequent evidence was required. 
One of the following case definitions 
had to be satisfied:
• definite TB: sputum culture-posi-
tive for Mycobacterium tuberculosis 
on two or more occasions (e.g. at 
screening and the first follow-up 
test);
• probable culture-positive TB: cul-
ture-positive for M. tuberculosis on 
one occasion (e.g. at screening or a 
follow-up test) plus the presence of 
a compatible clinical illness or ra-
diological evidence of TB, failure to 
respond to broad-spectrum antibiot-
ics, and a response to TB treatment 
at 1 month;
• probable culture-negative TB: cul-
ture-negative for M. tuberculosis plus 
radiological evidence of TB or the 
presence of progressive symptoms of 
TB, failure to respond to antibiotics, 
and a response to TB treatment at 
1 month.
Table 1. Study participants’ baseline characteristics, by HIV status, Zimbabwe, 2005
Characteristic HIV+ HIV− P-value
(n = 1858) (n = 7121)
Median age in yearsa (IQR) 32 (26–38) 25 (20–35) 0.001
No. of femalesb (%) 1292 (69.6) 4202 (59.0) < 0.001
No. of past TB treatmentc (%) 169 (9.1) 109 (1.5) < 0.001
No. of household TB contact in past 
2 yearsc (%)
299 (16.1) 867 (12.1) < 0.001
Alcohol (AUDIT zone score)d < 0.001
I (low risk or abstinent) (%) 1491 (81.0) 6052 (85.3)
II (in excess of low-risk intake) (%) 212 (11.5) 660 (9.3)
III (hazardous drinking) (%) 73 (3.9) 188 (2.7)
IV (possible alcohol dependency) (%) 76 (4.1) 197 (2.8)
Smokinge < 0.001
Never smoked (%) 1615 (86.9) 6412 (90.1)
Current smoker (%) 196 (10.6) 589 (8.2)
Former smoker (%) 47 (2.5) 117 (1.6)
AUDIT, Alcohol Use Disorders Identification Test; IQR, interquartile range; TB, tuberculosis.
a  The ages of two HIV− participants were unknown.
b  The sexes of one HIV+ and two HIV− participants were unknown.
c  Information on past TB treatment and household contact was missing for 1 HIV+ and 11 HIV− 
participants.
d  Information on alcohol consumption was missing for 24 HIV− and 6 HIV+ participants.
e  Information on smoking history was missing for three HIV− participants.
Table 2.  Prevalence of potential TB symptoms in study participants, by HIV status, 
Zimbabwe, 2005
Symptom Total 
(n = 8979)
No. HIV+ 
(n = 1858)
No. HIV− 
(n = 7121)
P-value
(%) (%) (%)
Cough for less than 2 weeks 186 (2.1) 43 (2.3) 143 (2.0) 0.41
Cough for 2 weeks or morea 333 (3.7) 153 (8.2) 180 (2.5) < 0.001
Haemoptysis in the last year 152 (1.7) 63 (3.4) 89 (1.3) < 0.001
Fever 340 (3.8) 158 (8.5) 182 (2.6) < 0.001
Mild night sweatsb 144 (1.6) 48 (2.5) 96 (1.3) < 0.001
Drenching night sweats 362 (4.0) 162 (8.7) 200 (2.8) < 0.001
Weight loss 441 (4.9) 203 (10.9) 238 (3.3) < 0.001
Any of the above 1102 (12.3) 394 (21.2) 708 (9.9) < 0.001
TB, tuberculosis.
a  A cough lasting 3 weeks or more was reported by 258 participants (2.9%): 129 (6.7%) HIV+ and 129 
(1.8%) HIV− (P < 0.001).
b  No need to change bed clothes or sheets.
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Laboratory methods
For participants with one or more 
symptoms, the two sputum specimens 
were processed separately for culture 
and sputum smears were read imme-
diately. For asymptomatic participants, 
a single pooled sputum specimen was 
cultured and the two smears were 
read only if the pooled culture tested 
positive (hence we can not comment 
on the sensitivity of screening smears). 
Smears were made from concentrated 
sputum decontaminated with 4% 
sodium hydroxide and read by fluores-
cence microscopy with auramine O. 
All positive and 10% of negative slides 
were re-read by a second reader. Each 
positive result was confirmed using 
Ziehl–Neelsen staining. Culture used 
Löwenstein-Jensen slopes, with the 
residual concentrate stored at −20 °C 
for re-culture in the event of contami-
nation. Species were identified using 
colony morphology, growth at different 
temperatures and growth on para-
Table 3.  Prevalence of specific sputum culture and smear screening test results 
and TB symptoms in 79 study participants with active TB, by HIV status, 
Zimbabwe, 2005
Bacteriology finding 
or symptom
Total No. HIV+ HIV− P-value
(n = 79) (n = 48) (n = 31)
(%) (%) (%)
Culturea and smear screening 
test results
0.27
Culture-positive, smear-positive 31 (39) 17 (35) 14 (45)
Culture-positive, smear-negative 23 (29) 14 (29) 9 (29)
Culture-negative, smear-negativeb 25 (32) 17 (35) 8 (26)
Symptom
Cough for less than 2 weeks 10 (13) 7 (15) 3 (10) 0.52
Cough for 2 weeks or more 37 (47) 23 (48) 14 (45) 0.81
Haemoptysis in the last year 7 (9) 7 (15) 0 (0) 0.026
Fever 28 (35) 18 (38) 10 (32) 0.63
Mild night sweatsc 5 (6) 2 (6) 3 (6) 0.97
Drenching night sweats 30 (38) 22 (46) 8 (26) 0.073
Weight loss 37 (47) 25 (52) 12 (39) 0.64
Any of the above 61 (77) 39 (81) 22 (71) 0.29
More than one TB symptomd 47 (59) 32 (67) 15 (48) 0.11
TB, tuberculosis.
a  Culture refers to growth of Mycobacterium tuberculosis in culture.
b  Follow-up cultures in participants who were diagnosed with TB despite being culture-negative on 
screening were positive in 4 (24%) HIV+ and 5 (63%) HIV− participants. All 16 participants who were 
consistently culture-negative were assessed for their response to TB treatment after 1 month. Of these, 
14 had radiological abnormalities that did not respond to treatment with amoxicillin and erythromycin 
but did respond to 1 month of TB treatment (including unilateral pleural effusion in 3 patients, miliary 
shadowing in 2 patients and pericardial effusion confirmed by echocardiography in 2 patients) and 2 
had clinical signs of TB that responded to TB treatment (namely ascites in 1 and asymmetrical cervical 
lymphadenopathy in 1).
c  No need to change bed clothes or sheets.
d  Symptoms included cough of any duration, haemoptysis in the last year, fever, night sweats and 
weight loss.
nitrobenzoic acid Löwenstein-Jensen 
slopes. Non-tuberculous mycobacteria 
were sent to the South African Institute 
for Medical Research in Johannesburg 
for further identification.
Confidential HIV serum testing 
was carried out with the Determine as-
say (Abbott Diagnostics, Johannesburg, 
South Africa), with all positive and 
10% of negative specimens confirmed 
by the Unigold test (Trinity Biotech, 
Dublin, Ireland). For participants who 
were not willing to provide serum, oral 
mucosal transudate was collected and 
tested using the Vironostika assay (Vi-
ronostika, BioMérieux, Marcy l’Etoile, 
France).
Ethical approval
Approval was granted by the Ethics 
Committees of the Biomedical Research 
and Training Institute, Harare, Zim-
babwe, the Medical Research Council 
of Zimbabwe, Harare, Zimbabwe, and 
the London School of Hygiene and 
Tropical Medicine, London, United 
Kingdom. Written informed con-
sent was provided by all participants. 
Confidential HIV tests were carried 
out and the results were stored using 
dedicated laboratory numbers, with no 
other personal identifiers. Voluntary 
counselling and testing were offered to 
all participants.
Statistical methods
Data were captured using EpiInfo 
2003 (Centers for Disease Control 
and Prevention, Atlanta, GE, USA) 
and analysed with STATA 9.0 software 
(STATA Corporation, College Station, 
TX, USA).
The sensitivity, specificity, positive 
predictive value (PPV) and negative 
predictive value (NPV) of symptoms 
and TB culture findings were calculated 
using the set of TB case definitions 
listed above as the reference or gold 
standard diagnosis. The area under the 
receiver operating characteristic curve 
(AUC) was also estimated to provide 
a summary measure of diagnostic ac-
curacy. A non-parametric test was used 
to compare different AUCs. Logistic 
regression analysis was used to investi-
gate risk factors for chronic cough and, 
in separate analyses, the relationship 
between TB disease and TB symptoms. 
There was no significant clustering of 
TB disease in communities or house-
holds (only three households had 
multiple TB cases), so in the analysis 
in which TB disease was the outcome, 
we did not adjust for clustering effects. 
However, for the analysis of TB symp-
toms, we used robust, or sandwich, 
standard errors to allow for clustering.
Results
Of the 10 076 participants who con-
sented to TB screening in the parent 
study, 93 were already on TB treatment 
(including 9 who were still culture-
positive) and 1004 declined HIV-
testing, leaving 8979 participants for 
this analysis. The participants’ baseline 
characteristics are shown by HIV status 
in Table 1.
TB symptoms
As shown in Table 2, all potential TB 
symptoms were significantly more 
common in the 1858 HIV+ than the 
7121 HIV− participants, except for 
acute cough. Overall, 21.2% of HIV+ 
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Table 4. ORs for TB disease among HIV− and HIV+ participants for different symptoms, recent household contact with TB and past 
TB treatment, as derived by unadjusted and adjusted multivariate logistic regression analysis, Zimbabwe, 2005
Symptom or other variable HIV− TB patients HIV+ TB patients
Unadjusted  
OR
Adjusted  
OR
95% CI for 
adjusted OR
Unadjusted  
OR
Adjusted  
OR
95% CI for 
adjusted OR
No cough (reference) 1 1 1 1
Cough for < 2 weeks 5.3 4.9 1.4–17.5 8.4 12.6 4.9–32.3
Cough for ³ 2 weeks 34.4 19.4 7.2–52.0 11.9 6.1 2.8–13.2
Haemoptysis 2.2a ND ND 5.4 1.3 0.4–4.1
Fever 19.1 2.8 0.8–9.5 7.2 0.9 0.4–1.9
No night sweats (reference) 1 1 1 1
Mild night sweatsb 5.1 1.4 0.4–5.0 2.6 1.3 0.4–4.9
Drenching night sweats 12.5 1.4 0.4–5.4 10.1 3.1 1.4–7.1
Weight loss 19.2 4.0 1.5–10.7 10.0 2.8 1.3–5.7
Household TB contact in past 2 years 1.7 1.0 0.4–2.3 1.4 1.0 0.5–2.3
Past TB treatment 4.5 1.2 0.1–10.4 2.1 1.1 0.4–3.0
CI, confidence interval, ND, not determined; OR, odds ratio, TB, tuberculosis.
a  Not significant (95% CI: 0.3–17.0), and so not included in the multivariate analysis.
b  No need to change bed clothes or sheets.
and 9.9% of HIV− participants had at 
least one symptom (P < 0.001). The 
most frequent symptoms were weight 
loss, in 4.9% of the total, and drench-
ing night sweats, in 4.0%. Chronic 
cough lasting 2 weeks or more was 
reported by 3.7% of participants: by 
8.2% of HIV+ and 2.5% of HIV− 
participants.
Newly diagnosed TB disease that 
met one of the above case definitions 
was observed in 79 participants, whose 
sputum culture and smear results and 
HIV status are shown in Table 3. 
Symptoms differed little by HIV sta-
tus (Table 3). Overall, 47 (59%) had 
cough, which was of 2 weeks’ duration 
or longer in 37 (47%). The next most 
common symptoms were unintention-
al weight loss in 47% and drenching 
night sweats in 38%. In 18 patients 
(24% of HIV+ and 22% of HIV− 
participants with TB disease), TB was 
detected by screening culture alone as 
they denied having any symptoms at 
baseline. They included 8 participants 
who also had smear-positive disease: 4 
HIV− and 4 HIV+.
Duration of symptoms
There was no significant difference in 
the reported duration of symptoms be-
tween participants with symptoms who 
had TB and those who did not, except 
that cough was significantly more pro-
longed in HIV− participants who also 
had TB (median: 4 weeks, interquartile 
range: 2–8 weeks) than in those whose 
cough was due to another cause (me-
dian: 2 weeks, interquartile range: 1–4 
weeks; P = 0.003). In HIV+ partici-
pants, however, cough due to another 
cause was also prolonged (median: 3.5 
weeks, interquartile range: 2–8 weeks) 
and not significantly different from 
cough associated with HIV-related TB 
(median: 4 weeks, interquartile range: 
2–8 weeks; P = 0.36).
Multivariate analysis
In general, TB patients with symp-
toms tended to be polysymptomatic. 
Multivariate logistic regression analysis 
was used to identify symptoms and 
other variables independently associ-
ated with TB disease (Table 4). Odds 
ratios (ORs) adjusted for other symp-
toms tended to be considerably lower 
than unadjusted ORs. For both HIV+ 
and HIV− TB, acute cough (adjusted 
OR: 4.9 for HIV− and 12.6 for HIV+ 
TB), chronic cough (adjusted OR: 
19.4 for HIV− and 6.1 for HIV+ TB) 
and weight loss (adjusted OR: 4.0 for 
HIV− TB and 2.8 for HIV-related TB) 
remained independent predictors of 
TB disease after adjustment. In addi-
tion, the presence of drenching night 
sweats was an independent predictor 
of HIV+ TB (adjusted OR: 3.1, 95% 
confidence interval: 1.4–7.1) but not 
of HIV− TB (adjusted OR: 1.4, 95% 
confidence interval: 0.4–5.4). Neither 
recent household contact with TB nor 
past TB treatment was significantly as-
sociated with TB after adjustment for 
symptoms.
Diagnostic utility
Measures of the utility of different 
screening strategies for TB disease in 
HIV− and HIV+ individuals are re-
ported in Table 5. Although HIV status 
did not have a significant effect on 
either sensitivity or specificity, PPVs 
were considerably higher in HIV+ 
participants.
No screening strategy was ideal: all 
missed some TB patients and the high-
est AUC for symptom-based screening 
was 0.82 for HIV− TB and 0.81 for 
HIV+ TB.
In a pooled analysis of HIV+ and 
HIV− TB suspects, prolonged cough 
had a sensitivity of 46.8% and a 
specificity of 96.7% for identifying 
TB disease. The sensitivity increased to 
59.5% for cough of any duration, with 
a significant increase in AUC from 0.72 
for chronic cough to 0.77 (P = 0.005). 
There was a further significant increase 
in AUC to 0.81 (P = 0.037 for the 
comparison with any cough) for weight 
loss or cough (sensitivity: 69.6%). The 
maximum sensitivity was 77.2% for 
the criterion of exhibiting any one or 
more of the five TB symptoms used to 
define a TB suspect. However, there 
was no significant increase in AUC 
compared with cough or weight loss 
because of falls in both specificity 
(from 91.7% for cough or weight loss 
to 88.3% for any symptom) and PPV 
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(from 6.9% for cough or weight loss to 
6.2% for any symptom).
The use of TB culture on solid cul-
ture media for screening for TB disease 
had a sensitivity of 68.4% and an AUC 
of 0.84. The specificity was just under 
100% because M. tuberculosis grew on 
specimens from 16 participants, in-
cluding 14 who were HIV−, in whom 
TB was not confirmed. Of these 16, 
6 had TB symptoms, while follow-up 
was suboptimal in 4 (2 of whom were 
both symptomatic and HIV+) because 
they refused further investigation or 
relocated. The 12 participants who 
were followed up were known to have 
remained clinically stable for several 
months while off TB treatment. The 
prevalence of TB symptoms (37.5%) 
in culture-positive individuals in whom 
TB was not confirmed was significantly 
higher than in culture-negative indi-
viduals without TB (11.7%, P = 0.007). 
There was no other significant differ-
ence in patient characteristics between 
these two groups.
Discussion
This study shows that some screening 
failures can be anticipated when either 
TB symptoms alone or M. tuberculo-
sis culture alone is used to screen for 
previously undiagnosed TB, even in 
HIV-infected individuals. For example, 
M. tuberculosis grew on culture of sputum 
specimens from 19 HIV− and 9 HIV+ 
participants who did not exhibit any of 
the five TB symptoms considered (i.e. 
cough, haemoptysis, fever, night sweats 
or weight loss) and, subsequently, 9 of 
the 19 HIV− and all 9 HIV+ participants 
had TB disease confirmed on follow-up. 
In addition, screening cultures were 
negative in 25 patients in whom TB 
disease was confirmed either by positive 
cultures on follow-up (4 HIV+ and 5 
HIV− participants) or from clinical and 
radiological responses to TB treatment 
(13 HIV+ and 3  HIV− participants).
The prevalence of TB symptoms 
was high in HIV+ participants and the 
sensitivity of initial symptom screening 
in these individuals ranged from 47.9% 
when chronic cough was used to define 
a TB suspect to 81.3% when any of the 
five TB symptoms considered was used. 
Symptom screening was more sensitive 
than sputum culture on a solid me-
dium, whose sensitivity was 64.6%. We 
found that the diagnostic performance 
of symptom screening in HIV+ partici-
pants, as assessed using the AUC, was 
significantly and incrementally better 
when acute cough of less than 2 weeks’ 
duration and weight loss were individu-
ally added to the cardinal symptom of 
chronic cough lasting 2 weeks or more. 
Broadening the definition of a TB sus-
pect further did not improve diagnostic 
performance. Nevertheless, PPVs were 
high for all symptoms among HIV+ 
participants, which supports using a 
less strict definition of a TB suspect 
in individuals known to have an HIV 
infection, even though specificities were 
suboptimal.
Although subclinical TB dis-
ease is rarely recognized in routine 
Table 5.  Diagnostic value of different symptoms and other variables and their combination for screening for TB disease in HIV− and 
HIV+ individuals, Zimbabwe, 2005
HIV status and symptom, other 
variable or combination
No. of 
participants 
with defined 
symptoms
No. of TB 
cases with 
defined 
symptoms
Sensitivity Specificity PPV NPV AUC
HIV− (n = 7121) (n = 31)
Cough for ³ 2 weeks 180 14 45.2 97.7 7.8 99.8 0.71
Any cough 323 17 54.8 95.7 5.3 99.8 0.75
Either of: cough or weight lossa 487 20 64.5 93.4 4.1 99.8 0.79
Any of: cough, drenching night sweats or 
weight lossb
582 22 71.0 92.1 3.8 99.7 0.82
Any symptom (i.e. cough, haemoptysis, fever, 
night sweats or weight loss)
708 22 71.0 90.3 3.1 99.9 0.81
Any symptom or recent household TB contact 1445 22 71.0 79.9 1.5 99.8 0.75
Sputum culture-positive for TB (regardless 
of symptoms)
37 23 74.2 99.8 62.2 99.9 0.87
HIV+ (n = 1858) (n = 48)
Cough for ³ 2 weeks 169 26 47.9 92.8 15.0 98.5 0.70
Any cough 196 30 62.5 90.8 15.3 98.9 0.77
Either of: cough or weight lossa 307 35 72.9 85.0 11.4 99.2 0.79
Any of: cough, drenching night sweats or 
weight lossb
354 36 75.0 82.4 10.2 99.2 0.79
Any symptom (i.e. cough, haemoptysis, fever, 
night sweats or weight loss)
394 39 81.3 80.4 9.9 99.4 0.81
Any symptom or recent household TB contact 609 39 81.3 68.5 6.4 99.3 0.75
Sputum culture-positive for TB (regardless of 
symptoms)
33 31 64.6 99.9 93.9 99.1 0.82
AUC, area under the receiver operating characteristic curve; NPV, negative predictive value; PPV, positive predictive value; TB, tuberculosis.
a  In a pooled analysis of HIV+ and HIV− TB cases, the AUC for any cough or weight loss was significantly larger than for any cough alone (P = 0.05) and the AUC for 
any cough was significantly larger than for cough ³ 2 weeks (P = 0.006). None of the alternative screening strategies considered performed significantly better than 
any cough or weight loss.
b  Cough, drenching night sweats and weight loss were all shown to be independent predictors of TB in the multivariate analysis (Table 4).
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Fig. 1. Effect of strong routine TB diagnosis and treatment programmesa on symptom 
and bacteriological profiles of residual TB cases that remain to be detected 
through provider-initiated TB screening
Culture-positive TB Smear-positive, culture-positive TB Smear-positive TB
a) Profile of prevalent TB
patients when access
to routine diagnosis
and treatment is limited
Severe symptoms
Mild symptoms
No symptoms
Severe
Mild
No
symptoms
Severe symptoms
Mild
- large percentage with symptomatic TB
- large percentage smear-positive
and culture-positive.
A  small percentage of patients with
asymptomatic, culture-negative TB
will be missed unless a third screening
test is used.
- small percentage with symptomatic TB
- small percentage smear-positive
and culture-positive.
Asymptomatic, culture-negative TB
will be proportionately more important because
symptomatic TB will be rapidly detected.
b) Residual burden of
undiagnosed TB under
strong routine
programmes
- all are symptomatic
- most are smear-positive
and culture-positive
by the time of
self-presentation
Most
severe TB
already
diagnosed
c) TB patients
treated by routine
TB services
TB, tuberculosis.
a  Routine diagnosis and treatment services rely on patients with TB symptoms presenting themselves and use 
the smear test as the first-line investigation. Consequently, highly symptomatic and smear-positive patients are 
more likely to be diagnosed (part c of figure) and residual undiagnosed cases (part b of figure) will tend to have 
mild symptoms or none and smear-negative disease. The more effective the routine service, the greater the shift 
towards minimally symptomatic or asymptomatic disease. Under the World Health Organization’s DOTS strategy, 
patients with chronic cough are particularly likely to be diagnosed, which leaves behind a higher proportion of 
symptomatic patients without chronic cough.
clinical practice, it is often observed 
during provider-initiated TB testing 
whenever a second screening modality 
(e.g. radiography or diagnostic bacte-
riology) is combined with symptom 
screening.7,9–16 Fig. 1 illustrates why 
the symptom and bacteriological pro-
files of TB patients identified through 
provider-initiated TB testing will tend 
to differ from those of patients diag-
nosed through routine TB clinical ser-
vices, especially when a strong routine 
diagnosis and treatment programme is 
in place. In the latter case, patients with 
highly symptomatic disease and those 
with “first-line” diagnostic features, 
such as chronic cough or a positive 
smear test result, will tend to be rapidly 
diagnosed and treated, leaving behind a 
residual burden of TB patients with less 
clinically obvious TB and those who 
have not sought care. Moreover, TB 
patients with more severe symptoms are 
more likely to be smear-positive, as are 
those whose symptoms include chronic 
cough.22,23 These factors help reconcile 
observations from provider-initiated 
prevalence surveys carried out in the 
pre-TB treatment era, when chronic 
cough had a high sensitivity for TB,22 
with observations from populations 
who now have access to TB diagnosis 
and treatment, in whom chronic cough 
is typically reported by only half or 
fewer of prevalent cases.7,9–16
In extreme cases, provider-initiated 
surveys of TB in populations with very 
easy access to TB diagnosis and treat-
ment have reported that all symptom 
combinations have very low sensitiv-
ity.12,14 This scenario should, in fact, be 
the aim of most HIV care clinics, where 
regular provider-initiated screening 
based on TB symptoms is now a World 
Health Organization recommendation.4 
Such screening is a valuable component 
of individual patient management and 
TB infection control, but health-care 
providers working in these settings 
should not, then, be surprised by the re-
sulting low sensitivity of TB symptoms 
for detecting undiagnosed TB.
In the community-based survey 
reported here, HIV infection was as-
sociated with a significantly increased 
burden of undiagnosed TB and also 
with a higher frequency of symptoms, 
including weight loss, fever, drenching 
night sweats and chronic cough. This 
higher frequency was due to increases 
in both TB and non-TB causes of 
symptoms, and so had little effect on 
the sensitivity or specificity of symptom 
screening. Neither recent household TB 
contact nor past TB treatment was an 
independent predictor of prevalent TB. 
Nor did these factors lead to an increase 
in the yield of TB detected, though 
their presence substantially increased 
the number of defined TB suspects and 
the cost of subsequent investigation. 
The value of including past TB treat-
ment as a “screening” question may be 
higher in some populations, in which 
up to half of prevalent TB cases report 
past TB treatment,24 but our results sug-
gest that including recent household 
TB contact is likely to be expensive and 
uninformative.
One major and important dif-
ference between HIV+ and HIV− 
participants was that the duration of 
cough had limited diagnostic utility 
in HIV+ participants, with both acute 
and chronic cough having similar odds 
ratios for TB. In contrast, in HIV− 
participants, the odds ratio for chronic 
cough was much higher than for acute 
cough. This difference was mainly due 
to chronic cough being common in 
HIV+ participants without TB. Acute 
cough, with or without radiological 
changes, has been reported to have 
a relatively high PPV for TB in both 
provider-initiated screening 6 and in 
self-presenting patients in areas where 
HIV is prevalent,25–28 and so should 
ideally be considered as a TB symptom 
in both these contexts.
The limitations of this survey are 
that the questionnaire used included 
a limited range of questions, chest ra-
diography was not included as a third 
screening modality and participants 
were not examined for signs of extra-
pulmonary TB. Consequently, we will 
have missed some cases of asymptom-
atic or minimally symptomatic, culture-
negative TB.6,11,14 In addition, we used 
solid media for TB culture, which have 
a lower sensitivity than some liquid cul-
ture systems such as the Mycobacterial 
Growth Indicator Tube,29 and we only 
examined sputum smears in symp-
tomatic or culture-positive patients. 
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Since our prevalence survey was pop-
ulation-based, the HIV+ participants 
included probably had different patient 
characteristics and a lower burden of 
undiagnosed TB than participants in 
surveys based in HIV clinics. We did 
not investigate the possibility that an-
tiretroviral use modified the burden of 
TB in HIV-infected participants, as in-
formation on HIV status and access to 
HIV care were both limited at the time 
of this survey. At baseline, we excluded 
nine culture-positive cases who were 
recently diagnosed with TB: including 
them would have increased the propor-
tion of TB patients with chronic cough 
from 47% to 51%.
In summary, we have shown that 
even smear-positive TB may be missed 
by symptom screening in HIV+ TB 
patients. Although the sensitivity 
and specificity of symptom screening 
were similar for HIV+ and HIV− par-
ticipants, the presence of symptoms in 
HIV+ participants had a higher PPV 
and a lower NPV. Although imperfect, 
three of the symptoms evaluated (i.e. 
cough, drenching night sweats and 
weight loss) were independently predic-
tive of TB and their combination had 
a NPV over 99% in HIV+ participants. 
This suggests that symptom screening 
alone may be able to identify, at least 
in some settings, a subset of patients 
who are at a low risk of undiagnosed 
TB and in whom antiretroviral therapy 
or isoniazid preventive therapy can 
be started without further screening. 
This suggestion would, however, need 
confirmation from prospective stud-
ies ideally conducted in settings with 
both high and low prevalences of TB, 
given the limitations of the current 
study design. Provider-initiated TB 
screening is one of the many aspects 
of TB–HIV management in urgent 
need of more effective and accessible 
TB diagnostic tools. Unnecessary TB 
investigations are costly for patient and 
provider alike, do not always result in 
diagnostic certainty and delay access 
to life-saving antiretroviral therapy 
and preventive TB treatment. Conse-
quently until better TB diagnostics for 
resource-poor settings become widely 
available, many providers of HIV care 
in Africa will remain in the unsatisfac-
tory position of having to weigh the 
adverse consequences of potentially 
avoidable screening failures against 
those of setting unrealistically high 
screening standards.  ■
Acknowledgements
We thank the survey participants and 
all staff members of the Biomedical 
Research and Training Institute, Ha-
rare, Zimbabwe for their contribution 
to this study. The study was funded by 
the Wellcome Trust, London, United 
Kingdom. Additional author affiliations 
are: Biomedical Research and Training 
Institute, Harare, Zimbabwe (ELC, 
AEB), National Institute of Health Re-
search, Harare, Zimbabwe (SSM) and 
the University of Zimbabwe College 
of Health Sciences, Harare, Zimbabwe 
(PRM).
Competing interests: None declared.
Résumé
Recherche des symptômes de la tuberculose à l’initiative du prestateur de services au Zimbabwe : valeur 
diagnostique et effet du statut VIH
Objectif Évaluer la valeur diagnostique de la recherche des 
symptômes de la tuberculose (TB) à l’initiative du prestateur et 
comment le statut VIH influe sur cette valeur diagnostique.
Méthodes Nous avons réalisé une analyse secondaire sur des 
participants sélectionnés au hasard parmi les sujets d’une enquête 
en communauté concernant la prévalence de la co-infection 
TB-VIH, menée à Harare, au Zimbabwe. Tous les participants 
ont répondu à un questionnaire portant sur cinq symptômes et 
ont fait l’objet d’une culture d’expectorations pour rechercher 
la tuberculose et d’un dépistage du VIH. Nous avons calculé la 
sensibilité, la spécificité et les valeurs prédictives positive et 
négative des différents symptômes et étudié la relation entre ces 
symptômes et la tuberculose maladie en utilisant l’analyse par 
régression.
Résultats Nous avons relevé un ou plusieurs symptômes de la 
tuberculose chez 21,2 % des 1858 participants positifs pour le 
VIH (VIH+) et chez 9,9 % des 7121 participants négatifs pour 
ce virus (p < 0,001). La tuberculose a ensuite été diagnostiquée 
chez 48 sujets VIH+ et chez 31 sujets VIH-. Cette maladie était 
présente de manière asymptomatique chez 18 individus positifs 
à la culture, dont 8 (4 pour chacun des statuts VIH) donnaient des 
frottis d’expectorations positifs. La toux, quelle que soit sa durée, la 
perte de poids et pour les participants VIH+ uniquement, la sudation 
nocturne, constituaient des facteurs prédictifs indépendants 
de la tuberculose. Chez les participants VIH+, la présence de 
toux pendant 2 semaines ou plus, chacun des symptômes et 
l’obtention d’une culture d’expectorations positive présentaient 
respectivement une sensibilité de 48, 81 et 65 %. Chez les 
participants VIH-, les sensibilités correspondantes valaient 
respectivement 45, 71 et 74 %. Les symptômes fournissaient 
donc une sensibilité et une spécificité similaires chez les deux 
types de participants, mais chez les sujets VIH+, ils avaient une 
valeur prédictive positive plus élevée et une valeur prédictive 
négative plus faible.
Conclusion La recherche des symptômes à l’initiative du 
prestateur peut laisser passer même des cas de tuberculose frottis 
positifs, en particulier chez les individus séropositifs pour le VIH. 
Le dépistage sur la base des symptômes est utile pour exclure 
la tuberculose, mais les pays démunis ont besoin d’urgence d’un 
meilleur outil pour diagnostiquer cette maladie.
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Resumen
Cribado de síntomas de tuberculosis a instancias del profesional en Zimbabwe: valor diagnóstico y efecto de 
la serología VIH
Objetivo Determinar el valor diagnóstico del cribado de síntomas 
de tuberculosis a instancias del profesional, así como la influencia 
de la serología VIH en dicho cribado.
Métodos Realizamos un análisis secundario a partir de 
participantes seleccionados aleatoriamente en una encuesta 
comunitaria de prevalencia de la coinfección tuberculosis-VIH 
realizada en Harare, Zimbabwe. Todos ellos respondieron a un 
cuestionario sobre cinco síntomas y se sometieron a pruebas 
del VIH y de cultivo de esputo para la tuberculosis. Calculamos 
la sensibilidad, la especificidad y los valores predictivos positivo 
y negativo de los diversos síntomas y realizamos un análisis 
de regresión para investigar la relación entre los síntomas y la 
tuberculosis.
Resultados Detectamos uno o más síntomas de tuberculosis 
en el 21,2% de 1858 pacientes VIH-positivos (VIH+) y el 9,9% de 
7121 participantes VIH-negativos (VIH-) (p < 0,001).  Posteriormente 
se diagnosticó tuberculosis en 48 participantes VIH+ y 31 
participantes VIH-. Sufrían tuberculosis asintomática 18 personas 
con cultivo positivo, 8 de las cuales (4 en cada grupo serológico) 
presentaron esputo positivo. La tos de cualquier duración, la pérdida 
de peso y, sólo en el caso de los participantes VIH+, la presencia de 
sudores nocturnos, fueron factores predictivos independientes de 
la tuberculosis. En las personas VIH+, la tos de más de  2 semanas 
de duración, la presencia de cualquiera de los síntomas y un cultivo 
de esputo positivo tuvieron una sensibilidad del 48%, 81% y 65%, 
respectivamente; entre los participantes VIH-, la sensibilidad fue del 
45%, 71% y 74%, respectivamente. Los síntomas presentaron una 
sensibilidad y especificidad similares en los pacientes VIH+ y VIH-, 
pero en los primeros tenían un mayor valor predictivo positivo y 
un menor valor predictivo negativo.
Conclusión Incluso la tuberculosis con baciloscopia positiva 
puede pasar desapercibida en el cribado de los síntomas realizado 
a instancias del profesional, especialmente en las personas VIH+. 
El cribado de los síntomas es útil para descartar la tuberculosis, 
pero se necesitan urgentemente mejores medios de diagnóstico 
de esta enfermedad para los entornos con recursos escasos.
صلخم
زديلإا سويرفب ىودعلا ةلاح يرثأتو ةيصيخشتلا ةميقلا :يوبابيمز في لسلا ضارعأ نع يرحتلا في ةياعرلا يمدقم ةردابم
 نع  يرحتلا  في  ةياعرلا  يمدقم  ةردابلم  ةيصيخشتلا  ةميقلا  سايق  :ضرغلا
.كلذ في زديلإا سويرفب ىودعلا ةلاح رثؤت فيكو لسلا ضارعأ
 في  ًايئاوشع مهؤاقتنا  ىرج ينكراشلم يوناث  ليلحتب  نوثحابلا  ماق  :ةقيرطلا
 زديلإا سويرفو لسلاب ةكترشلما ىودعلا راشتنا سايقل زكترلما-يعمتجم حسم
 ةسمخ  مضي  ًانايبتسا  ينكراشلما  عيمج  لمكأو  .يوبابيمزب  يراره  ةنيدم  في
 صيخشتل  رابتخاو  ،مغلبلا  في  لسلا  تايصعل  ةعرزم  مهل  يرجأو  ،ضارعأ
 ميقلاو  ،ةيعونلاو  ةيساسحلا  نوثحابلا  بسحو   .زديلإا  سويرفب  ىودعلا
 صيقتل  فوحتلا  ليلحت  اومدختساو  ،ضارعلأا  فلتخلم  ةيبلسلاو  ةيباجيلإا
.لسلا ضرمو ضارعلأا ينب ةقلاعلا
 نم  %21.2  في  لسلل  ثركأ  وأ  ًادحاو  ًاضرع  نوثحابلا  فشتكا  :تادوجولما
 فيو  ،زديلإا  سويرفب  ىودعلل  ينيباجيإ  اوناك  ينكراشلما  نم  ًاصخش  1858
 نم لقأ P( زديلإا سويرفب ىودعلل ينيبلس اوناك  ًاصخش 7121 نم %9.9
 اوناك  ينكراشلما  نم  ًاصخش  48  في  ًاقحلا  لسلا  صيخشت  ىرجو  .)0.001
 ىودعلل  ينيبلس  اوناك  ًاصخش  31  فيو  ،زديلإا  سويرفب  ىودعلل  ينيباجيإ
 ةعرزم تناكو  ًاصخش 18  في ضارعلأا ميدع لسلا  فِشُتكا  .زديلإا  سويرفب
 ةعومجم في عقي مهنم ةعبرأ لك( مهنم صاخشأ ةيناثم ،ةيباجيإ مهيدل مغلبلا
 لاعسلا ناك .ةيباجيإ مهيدل مغلبلا ةخاطل تناك )زديلإا ةلاح بسح ةفلتخم
 ىودعلل ينيباجيلإل ةبسنلاب لييللا قرعتلا ةرازغ و ،نزولا نادقفو ،ةدم يلأ
 ينكراشملل  ةبسنلابو  .لسلاب  ةباصلإل  ةلقتسم  تائبنم  طقف  زديلإا  سويرفب
 يواست  وأ  نم  بركأ  ةدلم  لاعسلل  ناك  ،زديلإا  سويرفب  ىودعلل  ينيباجيلإا
 ،%81 ،%48 اهردق تايساسح مغلبلا ةعرزم ةيباجيإو ،ضرع يأو ،ينعوبسأ
 تناك ،زديلإا سويرفب ىودعلل ينيبلسلا ينكراشملل ةبسنلابو ؛بيتترلاب %65
 ةيساسح ضارعلأل  ناكو  .بيتترلاب  %74  ،%71  ،%45  اهردق  تايساسحلا
 سويرفب  ىودعلل  ينيبلسلاو  ينيباجيلإا  ينكراشملل  ةبسنلاب  ةهباشتم  ةيعونو
 ةميقو لىعأ ةيباجيإ ةيؤبنت ةميق زديلإا سويرفل ينيباجيلإل ناك نكلو ،زديلإا
.نىدأ ةيبلس
 فاشتكا رذعت نكيم ،ةخاطلل ينيباجيلإا لسلا ضىرلم ةبسنلاب ىتح :جاتنتسلاا
 ،لسلا  ضارعأ  نع  يرحتلاب  ةياعرلا  يمدقم  ةردابم  دنع  مهيدل  ضارعلأا
 في  ضارعلأا  نع  يرحتلا  ديفيو  .لسلا  سويرفب  ىودعلل  ينيباجيلإا  مايسلاو
 عقاولما  في  لضفأ  صيخشت  يرفوتل  ةحلم  ةجاح  كانه  نكلو  ،لسلا  داعبتسا
.دراولما ةيرقفلا
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